ORM-10103 is primarily investigated for its potential therapeutic applications in cardiovascular diseases. It functions as a selective inhibitor of the sodium-calcium exchanger (NCX), a protein involved in regulating calcium levels within cardiac cells. By modulating NCX activity, ORM-10103 aims to prevent calcium overload, which is a critical factor in conditions like heart failure and arrhythmias. Its development focuses on improving cardiac function and reducing adverse events in patients with compromised heart health. Research is ongoing to evaluate its efficacy and safety in clinical settings, particularly for acute and chronic heart conditions.